Usually, as development progresses from preclinical to a more advanced clinical stage, reality begins to set in: problems become apparent that were not anticipated, efficacy may be less than expected or hoped for, and the safety margins may shrink to
Continue reading The Letermovir Top-Line Results are Out – Or Are They? → Like this: Like Loading...
Posted in Recent Literature, The News, The Viewpoint |
Tagged AIC246, Aicuris, anti-rejection drugs, antibiotic blog, brincidofovir, Chimerix, CMV terminase inhibitor, CMV therapy, cyclosporine, cytochrome P450, drug-drug interactions, ganciclovir, GCV, GvHD, Harald Reinhart, HSCT, Keytruda, Letermovir, maribavir, Merck, MK-8224, MK-8228, pembrolizumab, publication delay, ViroPharma |
A Phase 1 study evaluating tigecycline (Tygacil®) to treat refractory Acute Myeloid Leukemia is currently underway?  Niacin extended release tablets (nicotinic acid, Niaspan®) was associated with a significantly higher rate of infections (appendicitis, bronchitis, cellulitis) compared to placebo in
Continue reading Did you know that… → Like this: Like Loading...
Posted in Did you know...? |
Tagged acute myeloid leukemia, AIM-HIGH, aminoglycoside, AML, antifungal, calcineurin inhibitor, CARDS, cyclophilin binder, cyclosporine, DEB-025, HCV, HIV, ICU, M. pneumonia, macrolide, mTORC1, mycoplasma, Niacin, Niaspan, nicotinic acid, rapamune, rapamycin, sirolimus, tigecycline, Tygacil |